New vaccine offers complete protection against dengue and offers hope for Zika, study suggests

17 March 2016

Researchers have made an encouraging breakthrough with an experimental vaccine to protect against dengue, the most prevalent of the world's mosquito-borne viruses.

The encouraged researchers are now set to turn their attentions to developing a Zika vaccine to protect against that virus, which is increasingly being linked to neurological disorders and microcephaly, a severe birth defect in which babies are born with smaller heads and brains.

In a trial of 41 healthy adults, the research team found that one dose of TV003, a vaccine that induces antibodies to all four dengue virus serotypes, offered 100% protection, according to the study, published in US journal Science Translational Medicine.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK